|
Dr. Fairman is a program manager and experienced scientist in the use of cationic lipsome-DNA complexes in gene therapy. After receiving his Ph.D. in Chemistry from the University of Arkansas in 1992, Dr. Fairman conducted his postdoctoral training at M.D. Anderson Cancer Center specializing in the genetics of leukemia. While at M.D. Anderson his research focused on genetic abnormalities in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). He is an author of many research publications and review articles in the area of hematopoetic neoplasms.
In 1996, Dr. Fairman began his industrial experience with AmCell Corporation working to develop technologies to isolate fetal cells from maternal blood for cytogenetic analysis. During this time he was one of three inventors on a patent for PCR additives. In 1997 Dr. Fairman joined Valentis, Inc., where he managed the assay development group and conducted preclincial efficacy and toxicity studies. He is also a consultant on quantitative PCR/RT-PCR and in-situ PCR/RT-PCR at the University of California, Davis, Applied Biosystems and Celera Diagnostics.
Most recently, Dr. Fairman was the Director of Pharmacogenomics Research at Clingenix Inc. where he directed research in the application of pharmacogenomics to clinical development. During his time at Clingenix, Dr. Fairman was inventor on several patents involving the application of pharmacogenomics technologies. | 